OVERVIEW
PharmaceuticalsLSE: AZN

AstraZeneca

AstraZeneca is a pharmaceutical business engaged in the research, development and commercialisation of prescription medicines. It focuses on three therapy areas: Oncology, BioPharmaceuticals and Rare Disease. Total Revenue for 2025 was $58,739 million, of which Product Sales were $55,573 million. By country, US revenue was $23,970 million and China revenue was $6,636 million. The Group has one reportable segment under IFRS 8.

Market cap
—
EV
—
Price —Not shown: the annual report states no share price
EV/EBITDA
—
EV/EBIT
—
PER
—
PBR
—
Multiples use the fiscal year to 2025-12-31 (UK companies do not report quarterly)
Debt to net debt (US$B)
29.6Debt5.74−Cash23.9Net debt
Balance sheet as of 2025-12-31
RESULTS + BALANCE SHEET
Revenue (US$B)
37.4'21/1244.4'22/1245.8'23/1254.1'24/1258.7'25/12
EBITDA (US$B)
7.59'21/129.24'22/1213.6'23/1216.7'24/1219.5'25/12
Net income (US$B)
0.11'21/123.29'22/125.96'23/127.04'24/1210.2'25/12
Capital structure (2025-12-31)
Equity 62% / Debt 38% · D/E 0.61
Cash vs. debt (US$B) Net debt
'21/12 Cash etc. 6.40'21/12 Debt 30.8'21/12'22/12 Cash etc. 6.41'22/12 Debt 29.2'22/12'23/12 Cash etc. 5.96'23/12 Debt 28.6'23/12'24/12 Cash etc. 5.65'24/12 Debt 30.3'24/12'25/12 Cash etc. 5.745.74'25/12 Debt 29.629.6'25/12
Cash etc.Debt
EBITDA = operating profit + D&A (cash flow statement adjustment) / D&A includes impairment / Debt = borrowings + lease liabilities
SEGMENTS
2025-12-31 · US$M · Total Revenue
Consolidated
Single segment58,739
MAJOR SHAREHOLDERS
DTR5 notifications · as of 2026-01-31
1BlackRock, Inc. (2009-12-04)6.50%
2The Capital Group Companies, Inc. (2025-12-03)4.97%
3Wellington Management Group LLP (2020-07-21)4.20%
4Wellington Management Company LLP (2020-07-21)4.20%
5Investor AB (2019-04-03)3.33%
Percentages are disclosed shares as a percentage of issued share capital at 31 January 2026; date is the latest disclosure. The two Wellington rows are overlapping notifications within one group.
Source: major shareholders stated in the annual report (percentages at the time of notification)
SHARES & PRICE
as of 2025-12-31
Shares in issue1,551,000,000 (stated in millions)
Treasury shares—
Excluding treasury—
Price stated in annual report—
Sources (annual reports, ESEF/iXBRL via filings.xbrl.org)

Figures come from annual reports (ESEF/iXBRL). AI is used to read the summary, segments, major shareholders, share count and stated price, and every item links to its source report.

All UK companies